Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder
Shots:
- The approval is based on two P-III studies: The SAkuraStar & SAkuraSky studies involves assessing Enspryng as monothx. and in combination with IST vs PBO in 95 & 83 NMOSD patients who are AQP4 seropositive aged 18-74yrs. & 12-74yrs. respectively
- SAkuraStar & SAkuraSky results: 74% & 79% reduction in the risk of relapses respectively
- Enspryng (SC- q4w) is a mAb targeting IL-6R treatment. Additionally- Canada is the first country to receive health authority approval for Enspryng- offering a new treatment option for NMOSD
Ref: Newswire Canada | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com